Zobrazeno 1 - 10
of 1 270
pro vyhledávání: '"Laurent Peyrin-biroulet"'
Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID
Autor:
Bénédicte Caron, Philippe Seksik, Anthony Buisson, Pauline Wils, Guillaume Savoye, Carmen Stefanescu, David Laharie, Lucas Guillo, Vered Abitbol, Joelle Bonnet, Romain Altwegg, Lucine Vuitton, Driffa Moussata, Arnaud Bourreille, Amélie Biron, Cyrielle Gilletta, Mathurin Fumery, Stephane Nahon, Stephane Nancey, Houda Camara, Laurent Peyrin-Biroulet
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 17 (2024)
Background: Several adalimumab preparations are now available for patients with inflammatory bowel disease (IBD). Comparative satisfaction and tolerability are unknown. Objectives: This study investigated IBD patient satisfaction with approved adalim
Externí odkaz:
https://doaj.org/article/7ca0c8a49c264203b43510c27bcad604
Autor:
Laurent Peyrin‐Biroulet, Perttu Arkkila, Alessandro Armuzzi, Silvio Danese, Marc Ferrante, Jordi Guardiola, Jørgen Jahnsen, Edouard Louis, Milan Lukáš, Walter Reinisch, Xavier Roblin, Philip J Smith, Taek Kwon, Jeeyoung Kim, Sangwook Yoon, Dong-Hyeon Kim, Raja Atreya
Publikováno v:
BMC Gastroenterology, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background While indirect comparison of infliximab (IFX) and vedolizumab (VDZ) in adults with Crohn’s disease (CD) or ulcerative colitis (UC) shows that IFX has better effectiveness during induction, and comparable efficacy during maintena
Externí odkaz:
https://doaj.org/article/5d1ccaccfa3b4ae6bc5630baead360c9
Publikováno v:
Arquivos de Gastroenterologia, Vol 61 (2024)
ABSTRACT Inflammatory bowel diseases (IBD) currently impose an immense social and economic burden on society in terms of both direct and indirect healthcare costs. Their incurable and progressive nature results in an unavoidable lifetime expense. The
Externí odkaz:
https://doaj.org/article/94a04c66f7924eee895c4f7e34c6439b
Autor:
Shaji Sebastian, Laurent Peyrin-Biroulet, Silvio Danese, Séverine Vermeire, Simon Travis, Jean-Frederic Colombel, Brian G Feagan, Vipul Jairath, Guangyong Zou, Geert R D’Haens, William J Sandborn, Gordon W Moran, Christopher Ma, Peter Bossuyt, Daniel Green, Mark S Silverberg, Maria Kłopocka, Marek Horynski, Stefanie C McFarlane, Zhongya Wang, Shashi Adsul, Marcelo Freire, Gabriela Radulescu, Julie Sigler, Jurij Hanžel, Rocio Sedano, Naveen Arya, Melanie Beaton, William Harlan, Rima Petroniene, Lukasz Wolanski
Publikováno v:
BMJ Open Gastroenterology, Vol 11, Iss 1 (2024)
Introduction Symptoms, endoscopy and histology have been proposed as therapeutic targets in ulcerative colitis (UC). Observational studies suggest that the achievement of histologic remission may be associated with a lower risk of complications, comp
Externí odkaz:
https://doaj.org/article/90b48a3e247b434da3279f2d6dcef059
Autor:
Mariangela Allocca, Cecilia Dell’Avalle, Alessandra Zilli, Federica Furfaro, Ferdinando D'Amico, Vipul Jairath, David T. Rubin, Laurent Peyrin-Biroulet, Gionata Fiorino, Silvio Danese
Publikováno v:
EClinicalMedicine, Vol 71, Iss , Pp 102559- (2024)
Summary: Background: The Bowel Ultrasound Score (BUSS) accurately detects therapy-related changes by using the Simple Endoscopic Score for Crohn's disease (SES-CD) as the reference standard. We aimed to evaluate ultrasound remission as a treatment ta
Externí odkaz:
https://doaj.org/article/3dafaa182ef347dd850d3069c668a430
Autor:
Thomas Hunaut, Laurent Peyrin-Biroulet, Antoine Le Bozec, Adeline Germain, Corinne Gower-Rousseau, Charles Sabbagh, Guillaume Cadiot, Mathurin Fumery
Publikováno v:
Gastro Hep Advances, Vol 3, Iss 6, Pp 731-737 (2024)
Background and Aims: While the occurrence of colonic stricture in Crohn’s disease (CD) always raises concerns about the risk of cancer, the neoplastic risk associated with its stricture remains poorly known. Methods: All consecutive patients with c
Externí odkaz:
https://doaj.org/article/09fb1a3dbf764f0bb7eb3f101415ab35
Autor:
Laurent Peyrin-Biroulet, Jean-Frederic Colombel, Edouard Louis, Marc Ferrante, Satoshi Motoya, Remo Panaccione, Joana Torres, Ryan C. Ungaro, Kristina Kligys, Jasmina Kalabic, Javier Zambrano, Yafei Zhang, Geert D'Haens
Publikováno v:
Gastro Hep Advances, Vol 3, Iss 4, Pp 539-550 (2024)
Background and Aims: Early biologic therapy treatment has demonstrated better outcomes in Crohn’s disease (CD). We evaluated the impact of CD duration in patients with moderately to severely active CD treated with risankizumab therapy. Methods: Thi
Externí odkaz:
https://doaj.org/article/fa55166e9c4e42f79099e540030db28a
Autor:
Fabrizio Fanizzi, Ferdinando D’Amico, Isadora Zanotelli Bombassaro, Alessandra Zilli, Federica Furfaro, Tommaso Lorenzo Parigi, Clelia Cicerone, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese, Mariangela Allocca
Publikováno v:
Microorganisms, Vol 12, Iss 9, p 1755 (2024)
Gut microbiota dysbiosis has a critical role in the pathogenesis of inflammatory bowel diseases, prompting the exploration of novel therapeutic approaches like fecal microbiota transplantation, which involves the transfer of fecal microbiota from a h
Externí odkaz:
https://doaj.org/article/c03122fb22e24078b55f9c70748d6691
Autor:
Margaux Lelong, Régis Josien, Marianne Coste-Burel, Marie Rimbert, Céline Bressollette-Bodin, Stéphane Nancey, Guillaume Bouguen, Matthieu Allez, Mélanie Serrero, Ludovic Caillo, Cléa Rouillon, Pierre Blanc, David Laharie, Raphaël Olivier, Laurent Peyrin-Biroulet, Nina Dib, Astrid De Maissin, Céline Montuclard, Caroline Trang-Poisson, Fabienne Vavasseur, Géraldine Gallot, Mathilde Berthome, Cécile Braudeau, Justine Chevreuil, Arnaud Bourreille, Catherine Le Berre
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundPatients with inflammatory bowel disease (IBD) may have a modified immune response to SARS-CoV-2. The objectives were to evaluate the prevalence of COVID-19 in patients treated with infliximab or vedolizumab, to analyze the factors associat
Externí odkaz:
https://doaj.org/article/bb5aa4f5ef734067852b695ae42f61b4
Autor:
Luca Massimino, Alberto Barchi, Francesco Vito Mandarino, Salvatore Spanò, Luigi Antonio Lamparelli, Edoardo Vespa, Sandro Passaretti, Laurent Peyrin-Biroulet, Edoardo Vincenzo Savarino, Vipul Jairath, Federica Ungaro, Silvio Danese
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-13 (2023)
Abstract Background Eosinophilic esophagitis (EoE) is a chronic immune-mediated rare disease, characterized by esophageal dysfunctions. It is likely to be primarily activated by food antigens and is classified as a chronic disease for most patients.
Externí odkaz:
https://doaj.org/article/9b478278a4244bc1a852db93013ff577